Valacyclovir for the Suppression of Recurrent Genital Herpes in Human Immunodeficiency Virus-Infected Subjects

Journal of Infectious Diseases

Volumn 188, Issue 7, 2003, Pages 1009-1016

  DeJesus, Edwin ^a   Wald, Anna ^b   Warren, Terri ^c   Schacker, Timothy W ^d   Trottier, Sylvie ^f   Shahmanesh, Mohsen ^g   Hill, Joanne L ^g   Brennan, Clare A ^e,h  

^a Infectious Disease Consultants   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Westover Heights Clinic   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e GLAXOSMITHKLINE   (United States)

^f LAVAL UNIVERSITY   (Canada)

^g Whittall Street Clinic ^*

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VALACICLOVIR;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENITAL HERPES; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; FEMALE; HERPES GENITALIS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SIMPLEXVIRUS; VALINE;

EID: 0142042462     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/378416     Document Type: Article

References (16)

1. Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982; 73:229-35.
2. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310:1551-6.
3. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex reactivation after marrow transplantation. Ann Intern Med 1984; 100:823-8.
4. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993; 54: 595-605.
5. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998; 178:603-10.
6. Conant MA, Schacker TW, Murphy RL, et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002; 13:12-21.
7. Collins P, Oliver NM. Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir. J Antimicrob Chemother 1986; 18(Suppl B):103-12.
8. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002; 35(Suppl2):S173-82.
9. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, 1981.
10. Romanowski B, Aoki FY, Martel AY, Lavender EA, Parsons JE, Saltzman RL. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS 2000; 14:1211-7.
11. Schacker TW, Hu H, Koelle D, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. Ann Intern Med 1998; 128:21-8.
12. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718-25.
13. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immuno-deficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997; 76:369-80.
14. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis 1998; 177:48-56.
15. Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes simplex virus to acyclovir in Northwest England. Antimicrob Agents Chemother 1998; 42:868-72.
16. Reyes M, Shaikh N, Graber J, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163:76-80.